Pfizer is currently seen as significantly undervalued despite uncertainties from patent expirations and declining COVID revenues. The company maintains strong profitability with free cash flow margins expected above 30% through the decade, supporting a forward dividend yield over 6%. Growth prospects are bolstered by its oncology pipeline and the recent acquisition of Seagen, providing long-term potential beyond early clinical stages. Investors are encouraged to consider Pfizer as its solid business model and pipeline progress are currently underappreciated by the market.
Pfizer, Chevron, and AbbVie have delivered strong dividend returns in 2026 and are positioned for further growth in 2027. Pfizer aims for $35 per share driven by obesity and oncology products, Chevron targets $250 supported by Guyana projects and AI ...
Hedge funds have been steadily buying Pfizer shares, attracted by its 6.3% dividend yield and promising oncology drug pipeline. Despite challenges from upcoming patent expirations that could impact earnings, Pfizer's late-stage cancer treatments and ...
In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products b...
Fairholme Capital, led by Bruce Berkowitz, holds 76.43% of its portfolio in St. Joe Company, a Northwest Florida land developer, reflecting strong conviction as the company posted its highest Q2 revenue in 20 years with significant margin expansions....
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
